MedTrace Logo

An Energetic View on Creativity, Psychopathology and Intelligence: The Brain2Business Study

NCT05544877 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-10-26

No results posted yet for this study

Summary

The interventional part of the study aims to assess the acute effect of the Brain2Business (B2B) tool on creative thinking (primary objective) in adults with psychological disorders. Additionally, the study assesses the B2B effects on energy-related sensations and metabolism, technique adherence, gratefulness and goal-directed activation (secondary objectives) in adults with and without psychological disorders. The observational part of the study primarily aims to investigate the link between psychopathology, intelligence, energy-related sensations and metabolism validating the "c factor mito-bioenergetics" (CMB) model in a sample of adults with and without psychological disorders.

Conditions

  • General Psychopathology
  • Fatigue
  • Depressive Disorder, Major

Interventions

BEHAVIORAL

Integrated 5-day Gratitude Exercise and Behavioral Activation Program

The 5-day intervention integrates a brief behavioral activation (BA) and a gratefulness exercise (GE) program. BA is composed of a lab-based idea generation and planning phase as well as a home-based performing phase with regard to pleasurable activities. GE is a idea generation task about aspects in life participants are grateful for about. It is performed once lab-based and daily with a home-based diary.

Sponsors & Collaborators

  • Brain2Go AG

    collaborator UNKNOWN

  • greenTEG AG

    collaborator INDUSTRY

  • SOMNOmedics GmbH

    collaborator UNKNOWN

  • Psychiatrische Dienste Thurgau

    lead OTHER

Principal Investigators

  • Rainer Krähenmann, PD · Psychiatrische Dienste Thurgau

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-19
Primary Completion
2023-09-29
Completion
2023-10-04

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544877 on ClinicalTrials.gov